Christophe Hotermans

2.5k total citations · 1 hit paper
31 papers, 1.7k citations indexed

About

Christophe Hotermans is a scholar working on Pathology and Forensic Medicine, Oncology and Neurology. According to data from OpenAlex, Christophe Hotermans has authored 31 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 16 papers in Oncology and 5 papers in Neurology. Recurrent topics in Christophe Hotermans's work include Multiple Sclerosis Research Studies (16 papers), Polyomavirus and related diseases (16 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Christophe Hotermans is often cited by papers focused on Multiple Sclerosis Research Studies (16 papers), Polyomavirus and related diseases (16 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Christophe Hotermans collaborates with scholars based in United States, Belgium and Switzerland. Christophe Hotermans's co-authors include Gary Bloomgren, Sophia Lee, James Scanlon, Susan Goelz, Sandra Richman, Alfred Sandrock, Tatiana Plavina, Carmen Bozic, Meena Subramanyam and Gustave Moonen and has published in prestigious journals such as New England Journal of Medicine, Neurology and Journal of Neurology Neurosurgery & Psychiatry.

In The Last Decade

Christophe Hotermans

29 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

2012 878 citations Gary Bloomgren, Sandra Richman et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Christophe Hotermans

Since Specialization

Citations

This map shows the geographic impact of Christophe Hotermans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Hotermans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Hotermans more than expected).

Fields of papers citing papers by Christophe Hotermans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Hotermans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Hotermans. The network helps show where Christophe Hotermans may publish in the future.

Co-authorship network of co-authors of Christophe Hotermans

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Hotermans. A scholar is included among the top collaborators of Christophe Hotermans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Hotermans. Christophe Hotermans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Natalizumab extended interval dosing (EID) is associated with a reduced risk of progressive multifocal leukoencephalopathy (PML) than every-4-week (Q4W) dosing: Updated analysis of the TOUCH® Prescribing Program database (1988) 2020 ·Neurology ·Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan R. Metzger, Judith D. Goldberg, Xiaochun Li, Evan L. Riddle, Karen Smirnakis, Zheng Ren, Christophe Hotermans, Pei‐Ran Ho, Nolan Campbell	2
2	Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing 2019 ·Neurology ·Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan R. Metzger, Judith D. Goldberg, Xiaochun Li, Evan L. Riddle, Karen Smirnakis, Rachna Kasliwal, Zheng Ren, Christophe Hotermans, Pei‐Ran Ho, Nolan Campbell	116
3	Reduced risk of progressive multifocal leukoencephalopathy (PML) associated with natalizumab extended interval dosing (EID): updated analysis of the TOUCH® Prescribing Program database (S26.006) 2019 ·Neurology ·Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan R. Metzger, Judith D. Goldberg, Xiaochun Li, Evan L. Riddle, Karen Smirnakis, Rachna Kasliwal, Zheng Ren, Christophe Hotermans, Pei‐Ran Ho, Nolan Campbell	2
4	Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE 2019 ·BMC Neurology ·Jai Perumal, Robert J. Fox, Roumen Balabanov, Laura J. Balcer, Steven Galetta, (unknown), Sourav Santra, Christophe Hotermans, Lily Lee	40
5	Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY) 2018 ·Multiple Sclerosis and Related Disorders ·Stanley Cohan, Harold Moses, Jonathan Calkwood, Carlo Tornatore, (unknown), Kyle Smoot, Venkata Srikanth Meka, (unknown), Christophe Hotermans, Jason P. Mendoza, Monica Mann, Leslie Meltzer	42
6	Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis 2018 ·CNS Drugs ·Mark Gudesblatt, (unknown), (unknown), (unknown), Lori Fafard, Jeffrey Wilken, (unknown), Marijean Buhse, Sourav Santra, Christophe Hotermans, Lily Lee	15
7	Natalizumab Extended Interval Dosing Is Associated with a Reduction in Progressive Multifocal Leukoencephalopathy (PML) Risk in the Touch® Registry 2018 ·Lana Zhovtis Ryerson, John Foley, Ih Chang, Ilya Kister, Gary Cutter, Ryan R. Metzger, Judith D. Goldberg, Xiaochun Li, Evan L. Riddle, Bei Yu, Zheng Ren, Christophe Hotermans, Pei‐Ran Ho, Nolan Campbell	10
8	Real-World Clinical Outcomes in Relapsing-Remitting Multiple Sclerosis Patients who Switch from Natalizumab to Delayed-Release Dimethyl Fumarate: A Multicenter, Retrospective, Observational Study (STRATEGY) (P3.293) 2015 ·Neurology ·Stanley Cohan, Jonathan Calkwood, Christopher LaGanke, Carlo Tornatore, Harold Moses, Kyle Smoot, Monica Mann, (unknown), (unknown), Christophe Hotermans, Leslie Meltzer	6
9	Time course of clinical and neuroradiological effects of delayed‐release dimethyl fumarate in multiple sclerosis 2015 ·European Journal of Neurology ·Ludwig Kappos, Gavin Giovannoni, Ralf Gold, J. Theodore Phillips, Douglas L. Arnold, Christophe Hotermans, (unknown), Vissia Viglietta, Robert J. Fox, (unknown)	31
10	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results 2014 ·Journal of Neurology Neurosurgery & Psychiatry ·Helmut Butzkueven, Ludwig Kappos, Fabio Pellegrini, María Trojano, Heinz Wiendl, Ruchi Patel, (unknown), Christophe Hotermans, Shibeshih Belachew, (unknown)	142
11	Clinical Efficacy of BG-12 (Dimethyl Fumarate) for Relapsing–Remitting Multiple Sclerosis (RRMS) According to Prior Therapy: An Integrated Analysis of the Phase 3 DEFINE and CONFIRM Studies (P07.128) 2013 ·Neurology ·Michael Hutchinson, Ralf Gold, Robert J. Fox, Eva Havrdová, Gavin Giovannoni, Annie Zhang, Christophe Hotermans, (unknown), Katherine Dawson, Amit Bar‐Or	3
12	Gastrointestinal Tolerability Events in Relapsing–Remitting Multiple Sclerosis (RRMS) Patients Treated with Oral BG-12 (Dimethyl Fumarate) in DEFINE and CONFIRM (P01.164) 2013 ·Neurology ·Leslie Meltzer, Krzysztof Selmaj, Ralf Gold, Robert J. Fox, Eva Havrdová, Gavin Giovannoni, Amy Pace, Mark Novas, Christophe Hotermans, Katherine Dawson, J. Theodore Phillips	3
13	Timecourse of Treatment Effects of BG-12 (Dimethyl Fumarate) for Relapsing–Remitting Multiple Sclerosis (S41.005) 2013 ·Neurology ·Ludwig Kappos, Gavin Giovannoni, Ralf Gold, Robert J. Fox, J. Theodore Phillips, Christophe Hotermans, Annie Zhang, Vissia Viglietta, David Miller	2
14	Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy breakdown → 2012 ·New England Journal of Medicine ·Gary Bloomgren, Sandra Richman, Christophe Hotermans, Meena Subramanyam, Susan Goelz, (unknown), Sophia Lee, Tatiana Plavina, James Scanlon, Alfred Sandrock, Carmen Bozic	878
15	Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134) 2012 ·Neurology ·Ludwig Kappos, Shibeshih Belachew, Helmut Butzkueven, Fabio Pellegrini, María Trojano, Heinz Wiendl, (unknown), Christophe Hotermans	10
16	Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS 2011 ·Journal of Neurology ·Bianca Weinstock‐Guttman, Steven Galetta, (unknown), Eva Havrdová, Michael Hutchinson, (unknown), Paul O’Connor, J. Theodore Phillips, Chris H. Polman, William H. Stuart, Frances Lynn, Christophe Hotermans	53
17	Comparison of the Timed 25-Foot and the 100-Meter Walk as Performance Measures in Multiple Sclerosis 2011 ·Neurorehabilitation and neural repair ·Rémy Phan-Ba, Amy Pace, (unknown), (unknown), (unknown), Robert Hyde, Christophe Hotermans, Valérie Delvaux, (unknown), Gustave Moonen, Shibeshih Belachew	77
18	Repetitive transcranial magnetic stimulation over the primary motor cortex disrupts early boost but not delayed gains in performance in motor sequence learning 2008 ·European Journal of Neuroscience ·Christophe Hotermans, Philippe Peigneux, Alain Maertens de Noordhout, Gustave Moonen, Pierre Maquet	47
19	Early boost and slow consolidation in motor skill learning 2006 ·Learning & Memory ·Christophe Hotermans, Philippe Peigneux, Alain Maertens de Noordhout, Gustave Moonen, Pierre Maquet	88
20	Population Dynamics of CD4⁺ T Cells Lacking Thy‐1 in Murine Retrovirus‐Induced Immunodeficiency Syndrome (MAIDS) 1994 ·Scandinavian Journal of Immunology ·Michel Moutschen, (unknown), Manuel Deprez, (unknown), Christophe Hotermans, Maud Martin, Roland Greimers, Jacques Boniver	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact